<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04770948</url>
  </required_header>
  <id_info>
    <org_study_id>SPL822</org_study_id>
    <nct_id>NCT04770948</nct_id>
  </id_info>
  <brief_title>An RCT of 19G EBUS-TBNA Needle in Suspected Sarcoidosis</brief_title>
  <acronym>GUESS</acronym>
  <official_title>A Study Evaluating the Diagnostic Yield and Safety of the 19-GaUge vs 22-Gauge EBUS-TBNA Needle in Subjects With Suspected Sarcoidosis (GUESS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Postgraduate Institute of Medical Education and Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AIIMS, New Delhi</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Apollo Hospitals, Bengaluru</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jaipur Golden Hospital, New Delhi</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rajiv Gandhi Cancer Institute, New Delhi</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institute of Pulmonology, Medical Research, and Development, Mumbai</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>AIIMS, Bhopal</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Asian Institute of Gastroenterology, Hyderabad</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yashoda Hospitals, Hyderabad</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>City Clinic and Bhailal Amin General Hospital, Vadodara</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Postgraduate Institute of Medical Education and Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Sarcoidosis is an idiopathic disorder characterized by granulomatous inflammation involving&#xD;
      various organ systems. The lung and mediastinal lymph nodes are the most commonly involved&#xD;
      structures in sarcoidosis. In the presence of intrathoracic lymph nodes, transbronchial&#xD;
      needle aspiration (TBNA) is a useful diagnostic modality, which is now guided using&#xD;
      endobronchial ultrasound (EBUS).&#xD;
&#xD;
      We hypothesize that the 19-gauge EBUS-TBNA needle will have a higher yield as compared to the&#xD;
      conventional 22-gauge EBUS-TBNA needle in intrathoracic lymphadenopathy due to sarcoidosis.&#xD;
      In this study, we plan to evaluate the yield and safety of the 19-gauge needle vs. the&#xD;
      conventional 22-gauge EBUS-TBNA needle in patients with sarcoidosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sarcoidosis is an idiopathic disorder characterized by granulomatous inflammation involving&#xD;
      various organ systems. The disease is diagnosed based on a suggestive clinicoradiological&#xD;
      picture and the presence of non-caseating granulomas in the involved organ, after excluding&#xD;
      known causes of granulomatous inflammation. The lung and mediastinal lymph nodes are the most&#xD;
      commonly involved structures in sarcoidosis. Various bronchoscopic techniques such as&#xD;
      endobronchial biopsy (EBB), transbronchial biopsy (TBLB) and transbronchial needle aspiration&#xD;
      (TBNA) are commonly used for acquiring tissue samples.&#xD;
&#xD;
      In the presence of intrathoracic lymph nodes, TBNA is a useful diagnostic modality,&#xD;
      especially when combined with endobronchial and transbronchial biopsies. At most centers,&#xD;
      TBNA is now guided using endobronchial ultrasound (EBUS). The technique is minimally invasive&#xD;
      and also offers the advantage of a selection of the appropriate node for sampling based on&#xD;
      the ultrasonographic characteristics. Several studies have demonstrated the superiority of&#xD;
      EBUS-TBNA over conventional TBNA (TBNA performed without real-time guidance).&#xD;
&#xD;
      Several technical aspects of EBUS-TBNA have been studied to optimize the yield including the&#xD;
      number of aspirations or passes required per lymph node station, needle gauge (21 vs. 22&#xD;
      gauge), suction pressure, the distance travelled by the needle within the lymph node, the&#xD;
      number of needle agitations required during a pass, and others.&#xD;
&#xD;
      The novel 19-G Vizishot FLEX EBUS needle (Olympus) is composed of a more flexible material&#xD;
      (nitinol) than the 22-G EBUS needle. This allows it to have a larger inner diameter with the&#xD;
      same outer diameter as a 22-G EBUS needle. Recent studies have shown that the 19-G needle is&#xD;
      safe and has a comparable yield to smaller bore needles. In case of suspected lymphadenopathy&#xD;
      due to malignant disorders, aspiration using smaller gauge needles may yield sufficient&#xD;
      material for diagnosis. However, in sarcoidosis, larger nodal tissue obtained with a thicker&#xD;
      bore needle, the 19-gauge needle, may potentially increase the identification of granulomas.&#xD;
      We hypothesize that the 19-gauge EBUS-TBNA needle will have a higher yield as compared to the&#xD;
      conventional 22-gauge EBUS-TBNA needle in intrathoracic lymphadenopathy due to sarcoidosis.&#xD;
      In this study, we plan to evaluate the yield and safety of the 19-gauge needle vs. the&#xD;
      conventional 22-gauge EBUS-TBNA needle in patients with sarcoidosis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">March 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Diagnostic yield of EBUS-TBNA samples</measure>
    <time_frame>6 months</time_frame>
    <description>Specimen showing epithelioid cell granulomas or collection of epithelioid cells with a giant cell (or asteroid body or Schaumann body).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adequacy of EBUS-TBNA samples</measure>
    <time_frame>7 days</time_frame>
    <description>Specimen shows a preponderance of lymphocytes or is diagnostic</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complication rate</measure>
    <time_frame>7 days</time_frame>
    <description>Complication associated with EBUS-TBNA procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cough visual analog scale (VAS)</measure>
    <time_frame>1 day</time_frame>
    <description>Operator-rated visual analog scale (VAS) score for the intensity of subject's cough</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Operator VAS</measure>
    <time_frame>1 day</time_frame>
    <description>VAS score for ease of performance of the needle puncture and aspiration rated by the operator</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Sarcoidosis</condition>
  <arm_group>
    <arm_group_label>19G</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>19 gauge EBUS-TBNA needle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>22G</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>22 gauge EBUS-TBNA needle</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>19 gauge needle</intervention_name>
    <description>EBUS-TBNA performed using 19G needle</description>
    <arm_group_label>19G</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>22 gauge needle</intervention_name>
    <description>EBUS-TBNA performed using 22G needle</description>
    <arm_group_label>22G</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: All the following&#xD;
&#xD;
          -  Age at least 18 years&#xD;
&#xD;
          -  Clinicoradiological suspicion of sarcoidosis where EBUS-TBNA is being planned&#xD;
&#xD;
          -  Enlarged bilateral hilar and/or mediastinal lymph nodes &gt;10 mm (any axis) on computed&#xD;
             tomography of the chest&#xD;
&#xD;
          -  Ability to provide informed consent to participate in the study.&#xD;
&#xD;
        Exclusion Criteria: Patients with any of the following will be excluded&#xD;
&#xD;
          -  Asymmetric lymph nodes&#xD;
&#xD;
          -  Lymph nodes with significant hypodense areas suggestive of necrosis&#xD;
&#xD;
          -  Tuberculin skin test &gt;10 mm&#xD;
&#xD;
          -  Hypoxemia (SpO2 &lt;92% on FiO2 of 0.3)&#xD;
&#xD;
          -  Treatment with systemic glucocorticoids for &gt;2 weeks in the preceding three months&#xD;
&#xD;
          -  Diagnosis of sarcoidosis possible with another minimally invasive technique such as&#xD;
             skin biopsy or peripheral lymph node biopsy&#xD;
&#xD;
          -  Failure to provide informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sahajal Dhooria, MD, DM</last_name>
    <phone>7087002015</phone>
    <email>sahajal@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ritesh Agarwal, MD, DM</last_name>
    <phone>7087007625</phone>
    <email>riteshpgi@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>PGIMER</name>
      <address>
        <city>Chandigarh</city>
        <zip>160012</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sahajal Dhooria, MD, DM</last_name>
      <phone>7087002015</phone>
      <email>sahajal@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Ritesh Agarwal, MD, DM</last_name>
      <phone>7087007625</phone>
      <email>riteshpgi@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 22, 2021</study_first_submitted>
  <study_first_submitted_qc>February 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 25, 2021</study_first_posted>
  <last_update_submitted>February 22, 2021</last_update_submitted>
  <last_update_submitted_qc>February 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Postgraduate Institute of Medical Education and Research</investigator_affiliation>
    <investigator_full_name>Ritesh Agarwal</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoidosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

